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Abstract
The protein alpha-synuclein whose expression is strongly
implicated in Parkinson’s disease (PD) is not only expressed
in the CNS but also in the enteric nervous system (ENS). The
growing body of evidence suggesting that gastrointestinal
inﬂammation is involved in the development of PD led us to
investigate the effects of inﬂammation on alpha-synuclein
expression in primary culture of rat ENS and in mice with
dextran sulfate sodium-induced colitis. Using western blot and
qPCR, we found that both lipopolysaccharide and a combina-
tion of tumor necrosis factor-a and interleukin 1-b decreased
the expression levels of alpha-synuclein in primary culture of
rat ENS, an effect that was prevented in the presence of the
p38 inhibitors SB203580 and BIRB 796. Lipopolysaccharide
and tumor necrosis factor-a/interleukin 1-b had no effect on
alpha-synuclein expression in primary culture of rat CNS and
in human erythroid leukemia cells. In mice, acute but not
chronic dextran sulfate sodium-induced colitis was associated
with a decreased expression of colonic alpha-synuclein. As a
whole, our ﬁndings indicate that acute inﬂammatory insults
down-regulate alpha-synuclein expression in the ENS via a
p38 pathway. They provide new insights into the widely
discussed concepts of alpha-synuclein expression and aggre-
gation in the ENS in PD and raise issues about the possible
role of gastrointestinal inﬂammation in the development of PD.
Keywords: alpha-synuclein, colitis, enteric nervous system,
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The protein alpha-synuclein is linked both genetically and
neuropathologically to Parkinson’s disease (PD). Missense
mutations of alpha-synuclein are responsible for autosomal
dominant forms of PD (Polymeropoulos et al. 1997; Kr€uger
et al. 1998; Zarranz et al. 2004) and Lewy bodies and
neurites, the deﬁning neuropathological characteristics of
the disease, are primarily composed of aggregated alpha-
synuclein (Spillantini et al. 1997). In addition, there is now
a large body of evidence implicating the expression levels
of alpha-synuclein in PD. Both duplications and triplica-
tions of the alpha-synuclein gene have been identiﬁed in
familial forms of the disease (Singleton et al. 2003;
Chartier-Harlin et al. 2004; Iba~nez et al. 2004) and analysis
of brain from sporadic PD subjects showed higher expres-
sion of alpha-synuclein mRNA compared to controls
(Gr€undemann et al. 2008). Overall, these ﬁndings indicate
that the mere over-expression of alpha-synuclein is sufﬁ-
cient to cause genetic PD, and that a subtle alteration of
alpha-synuclein expression may be critically involved in the
development of sporadic cases of the disease (Devine et al.
2011).
An accumulating body of literature has emerged in the past
25 years to show that PD is not only disorder of the brain but
also of the gastrointestinal (GI) tract and more generally
speaking of the brain–gut axis (Lebouvier et al. 2009;
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Derkinderen et al. 2011). GI symptoms occur in almost
every PD patient at some point (Edwards et al. 1992) and
autopsy studies have consistently shown that alpha-synuclein
aggregates are found in the enteric nervous system (ENS) in
nearly every case examined pathologically (Wakabayashi
et al. 1988; Beach et al. 2010; Gelpi et al. 2014). Why
alpha-synuclein accumulates in the enteric neurons is still
debated, but numerous ﬁndings support a role for local
inﬂammation. Two studies conducted in rodents suggest that
gut microbial-induced inﬂammation may foster alpha-
synuclein expression/aggregation, one through production
of lipopolysaccharide (LPS) (Choi et al. 2018), the other via
bacterial amyloid and cross seeding (Chen et al. 2016). A
recent study reported more alpha-synuclein immunostaining
in duodenal biopsies from pediatric patients with upper-GI
tract inﬂammation (Stolzenberg et al. 2017). Regarding PD,
higher expression levels of colonic pro-inﬂammatory cytoki-
nes, including tumor necrosis factor-alpha (TNF-a) and
interleukin 1-beta (IL1-b) (Devos et al. 2013) as well as
elevated fecal markers of inﬂammation (Houser et al. 2018;
Schwiertz et al. 2018) have been observed in PD patients
when compared to controls. The potential role of GI
inﬂammation in the development of PD is further reinforced
by the results of two large cohort studies, which showed a
signiﬁcant association between inﬂammatory bowel disor-
ders and the subsequent occurrence of PD (Peter et al. 2018;
Villumsen et al. 2018).
As a whole, these observations support the assumption that
inﬂammation might regulate enteric alpha-synuclein expres-
sion and therefore we set out to examine the regulation of
alpha-synuclein expression in vitro in rat primary culture of
ENS and in vivo in a mouse model of colitis.
Material and methods
Cell culture
Primary cultures of rat ENS were generated and cultured as
previously described (Coquenlorge et al. 2014). Brieﬂy, small
intestine of rat embryos E15 (20–28 per isolation from two pregnant
Sprague–Dawley rats (Janvier Laboratories SA, Le Genest-St-Isle,
France) were removed and ﬁnely diced in Hanks’ Balanced Salt
Solution (Sigma, Saint Quentin Fallavier, France, Cat# H9259).
Tissue fragments were collected in 8 mL of Dulbecco’s modiﬁed
Eagle medium (DMEM-F12) (1 : 1) (Gibco, Life Technologies,
Cergy-Pontoise, France, Cat# 31330-038) and digested at 37°C for
15 min in 0.1% (w/v) trypsin (Sigma, Cat# T1426). The trypsin
reaction was stopped by adding 20 mL of medium containing 10%
(v/v) fetal bovine serum (Sigma, Cat# F2442) and then treated by
0.01% (w/v) DNAse I (Sigma, Cat# DN25) for 10 min at 37°C.
After trituration with a 10 mL pipette, cells were centrifuged at
750 rpm for 10 min. Cells were counted and then seeded at a
density of 2.4.105 cells/cm² on 24-well plates previously coated for
2 h with a solution of 0.5% (w/v) gelatin (Sigma, Cat# G6144) in
sterile phosphate-buffered saline (PBS) (Gibco, Life Technologies,
Cat# 10010023). After 24 h, the medium was replaced with a
serum-free DMEM-F12 (1 : 1) medium containing 1% (v/v) of N-2
supplement (Life Technologies, Cat# 17502-048). Cells were
maintained in culture for 17 days.
For primary culture of CNS cortical neurons, cortex of rat
embryos E15 was dissociated mechanically and digested at 37°C for
15 min in 0.1% (w/v) trypsin (Sigma, Cat# T1426). The trypsin
reaction was stopped by adding DMEM-F12 (1 : 1) medium
(Gibco, Life Technologies Cat# 31330-038) containing 10% (v/v)
fetal bovine serum (Sigma, Cat# F2442) and then treated by 0.01%
(w/v) DNAse I (Sigma, Cat# DN25) for 10 min at 37°C. After
trituration with a 10 mL pipette, cells were centrifuged at 750 rpm
for 10 min. Cells were counted and then seeded at a density of
150 000 cells per well on 24-well plates previously coated for 2 h
with a solution of 0.5% (w/v) gelatin (Sigma, Cat# G6144) in sterile
PBS (Gibco, Life Technologies, Cat# 10010023).
Human erythroid leukemia cells (HEL 92.1.7; ATCC Cat# TIB-
180, research resource identiﬁer, RRID#CVCL_2481; LGC Stan-
dards, Molsheim, France) were cultured in RPMI 1640 (Sigma, Cat#
21875-034) supplemented with 10% (v/v) fetal bovine serum,
50 units/mL penicillin, and 50 lg/mL streptomycin (Life Tech-
nologies, Cat#15140-122) at densities from 0.2 to 1.5.10⁶ cells/mL.
This cell line is not listed as a commonly misidentiﬁed cell line by
the International Cell Line Authentication Committee and was
authenticated in June 2017.
DSS-induced colitis
Two different models of colon inﬂammation were studied in male
C57BL/6NRJ (8 weeks, Janvier) mice. Acute colitis was induced by
4% (w/v) Dextran Sulfate Sodium (36–50 000 kDa; MP Biomed-
icals, Illkirch, France, Cat# ICN216011080) in the drinking water
for 4 days, while chronic colitis was obtained by three cycles of 2%
(w/v) DSS in drinking water for 2 days followed by 5 days of water.
The corresponding control groups of animals were treated with
regular water for the same period. For acute colitis experiments,
controls and DSS-treated mice were killed by cervical dislocation on
days 1, 2, 3, and 4 (n = 5 per group). For chronic colitis
experiments, controls and DSS-treated mice were killed on day 18
(n = 10 per group). Samples of transverse and distal colon were
taken and stored at 80°C in lysis buffer RA1 (Macherey-Nagel,
Hoerdt, France, Cat# 740961.500) for further analysis by PCR and
western blot. No randomization was performed.
All housing and experimental procedures for mice and pregnant
rats were carried out in compliance with the local ethical review
panel of INSERM (agreement E. 44011; INSERM, Nantes, France)
and in accordance with the Council Directive 2010/63EU of the
European Parliament and the Council of 22 September 2010 on the
protection of animals used for scientiﬁc purposes. Animals were
housed in standard 42 9 26 9 15 cm plastic cages. Bedding
consisted of kiln-dried aspen shavings (SAFE, Augy, France).
Water and food were available (SAFE) ad libitum. Animals were
housed at 19–22°C, humidity 55%, and 12 : 12 h light: dark cycle
with lights on at 07:30.
Treatment of cells
After 14 days in vitro, cells were treated with LPS (Sigma,
Cat#L2630), TNF-a (Sigma, Cat#T6674), interleukin 1-b (Sigma,
Cat#I9401), interleukin-6, interleukin-10, interferon-c (Preprotech,
Neuilly-sur-Seine, France, Cat#200-06, 200-10, and 300-02
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respectively), SB 203580 (Merck, Calbiochem, Fontenay sous bois,
France, Cat#559395), BIRB 796 (Tocris, Lille, France, Cat#5989),
and 6o (Tocris, Cat# 3222) for the indicated period of time.
Western blot
Cells were harvested and lysed in radioimmunoprecipitation assay
buffer (Merck Millipore, Fontenay sous Bois, France, Cat# 20-188)
containing 2 mM orthovanadate (Sigma, Cat# S6505), phosphatase
inhibitor cocktail II (Sigma, Cat# P5726), and a protease inhibitors
cocktail (Sigma, Cat# 11697498001). Colonic samples stored in RA1
buffer were lysed with the ‘Precellys 24’ tissue homogenizer (Bertin
Technologies, Montigny-le-Bretonneux, France, Cat# P000669-
PR240-A) and total proteins were precipitated using protein precip-
itator and re-suspension buffer (protein solving buffer and tris(2-
carboxyethyl)phosphine-reducing agent) from NucleoSpin Triprep
Kit (Macherey-Nagel, Hoerdt, France, Cat# 740966) according to the
manufacturer’s instructions. Samples were further prepared for
electrophoresis by diluting with NuPAGE sample buffer (Life
Technologies, Saint-Aubin, France, Cat# NP0008) then heated at
98°C for 5 min. Lysates were separated using the NuPAGE 4–12%
Bis-Tris gels (LifeTechnologies,Cat#NP0336BOX) togetherwith the
2-(N-morpholino)ethanesulfonic acid/sodiumdodecyl sulfate running
buffer (Life Technologies, Cat# IB23002) before electrophoretic
transfer to nitrocellulose membranes (Life Technologies, Cat#
NP0002) with the iBlotTM Dry Blotting System (Life Technologies,
Cat# IB21001). Nitrocellulose membranes were treated with 4% (v/v)
paraformaldehyde and 0.01% (v/v) glutaraldehyde (Cat#G6257,
Sigma) in order to enhance membrane retention of alpha-synuclein
(Sasaki et al. 2015). Membranes were then blocked for 1 h at 21°C in
Tris-buffered saline (Sigma, Cat# T5912) with 0.1% (v/v) Tween-20
(Sigma, Cat# P1379) and 5% (w/v) non-fat dry milk and incubated
overnight at 4°C with the following primary antibodies: rabbit
polyclonal anti-alpha-synuclein (C-20)-R (1 : 1000; Santa Cruz
Biotechnology, Heidelberg, Germany, Cat# sc-7011-R, RRID:
AB_2192953), mouse monoclonal anti-alpha-synuclein Syn-1
(1 : 1000; BD Bioscience, Le Pont-de-Claix, France, Cat# 610787,
RRID:AB_398108), mouse monoclonal anti-PGP 9.5 (1 : 2000;
Thermo Fischer Scientiﬁc, Saint Herblain, France, Cat# MA1-83428,
RRID:AB_935198), mouse monoclonal anti-b-actin (1 : 10000;
Sigma, Cat#A5441, RRID:AB_476744) rabbit polyclonal anti-
phospho-p38, -phospho-JNK, -p38, and -JNK (1 : 1000; Cell signal-
ing,Ozyme, SaintQuentin enYvelines, FranceCat#9211, 9251, 9212,
and 9252; RRID:AB_331641, AB_331659, AB_330713,
AB_2250373, respectively), and mouse monoclonal anti-toll-like
receptor 4 (TLR4) (Novus, Bio-Techne, Lille, France, Cat# NB100-
56566, RRID:AB_2205129). Bound antibodies were detected with
horseradish peroxidase-conjugated anti-rabbit (Life Technologies
Cat# 31460, diluted 1 : 5000) or anti-mouse antibodies (Sigma, Cat#
A9044, diluted 1 : 5000) and visualized by enhanced chemilumines-
centdetection (Biorad,ClarityECL,Marnes-la-Coquette,France,Cat#
170-5061). For quantiﬁcation, the relevant immunoreactive bands
were quantiﬁed with laser-scanning densitometry and analyzed with
NIH Image J software (Bethesda, MD, USA) (version 1.51). To allow
comparison between different ﬁlms, the density of the bands was
expressedasapercentageof theaverageofcontrols.Thevalueofalpha-
synuclein immunoreactivitywasnormalized to the amount of PGP9.5,
while phospho-p38 and -JNK immunoreactivity were normalized to
p38 and JNK immunoreactivity, respectively.
Quantitative PCR analysis
RNAextractionfromentericprimaryculturewasperformedwithRNAeasy
Minikit (Qiagen S.A., Courtaboeuf, France, Cat# 74104) according to the
manufacturer’s instructions. The following primers were used:
• Alpha-synuclein # NM_019169.2, forward: 5’-GGCAAG
GGTGAAGAAGGGTA-30; reverse: 50-GTCTTGGTAG
CCTTCCTGAA-30
• Ribosomal protein S6 # NM_017160.1, forward: 50-GCA
TTGTGGATGCCAACCTG-30; reverse: 50-GTCCTGGG
CTTCTTACCTTCTT-30
For colonic tissues stored in RA1 buffer, RNA extraction was
performed with NucleoSpin Triprep Kit (Macherey-Nagel, Hoerdt,
France, Cat# 740966) according to the manufacturer’s instructions.
One lg puriﬁed mRNA was denatured and processed for reverse
transcription using Superscript III reverse transcriptase (Thermo
Fisher Scientiﬁc, Saint-Herblain, France, Cat # 18080044). PCR
ampliﬁcations were performed using the Absolute Blue SYBR green
ﬂuorescein kit (Roche Molecular Biochemicals, Meylan, France,
Cat# AB4166B) and run on a StepOnePlus system (Life Technolo-
gies, Cat# 4376600). The following primers were used:
• TNFa # NM_013693.3, forward: 50-GAACTTCGGGGT
GATCGGTCC-30; reverse: 50-GCCACTCCAGCTGCTC
CTCC-30
• IL-1b # NM_008361.4, forward: 50-GCCTCGTGCTG
TCGGACCCATA-30; reverse: 50-TTGAGGCCCAAGG
CCACAGGT-30
• Ribosomal protein S6 # NM_001010.2, Forward: 50-CCA
AGCTTATTCAGCGTCTTGTTACTCC-30; Reverse: 50-
CCCTCGAGTCCTTCATTCTCTTGGC-30
Immunohistochemistry
Primary culture of rat ENS was ﬁxed in PBS with 4% (v/v)
paraformaldehyde at 21°C for 30 min. Following pre-incubation in
PBS containing 5% (v/v) donkey serum and 0.5% (v/v) TritonTM X-
100 (Sigma, Cat # X100) for 30 min, cells were incubated with the
following primary antibodies overnight at 4°C: mouse monoclonal
anti-alpha-synuclein Syn-1 (1 : 1000; BD Bioscience, Cat#
610787), rabbit monoclonal anti-rat alpha-synuclein D37A6
(1 : 500; Cell Signaling Ozyme, Saint Quentin en Yvelines, France,
Cat#4179, RRID:AB_1904156), mouse monoclonal anti-HuC/D
(1 : 200; Life Technologies, Cat#A21-271, RRID:AB_221448),
mouse monoclonal anti-b-tubulin III (1 : 1000; Sigma, Cat# T8328,
RRID:AB_1844090), rabbit polyclonal anti-S100b (1 : 1000; Agi-
lent, Dako Omnis, Courtaboeuf Les Ulis, France, Cat# GA50461-2),
mouse monoclonal anti-TLR4 (1 : 1000, Novus, Cat# NB100-
56566, RRID:AB_2205129), and goat polyclonal anti-a-smooth
muscle actin (1 : 500; Abcam, Paris, France, Cat# ab21027). After
secondary antibodies, images were acquired with an Olympus IX 50
ﬂuorescence microscope.
Cell viability and neuronal damage assays
Evaluation of neuronal damage was performed using neuron-
speciﬁc enolase (NSE) release into the culture medium and counting
of Hu-immunoreactive neurons. NSE released in the culture
supernatant was quantiﬁed using a rat NSE ELISA kit
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(MyBioSource, Catalog #MBS2508955; CliniSciences, Nanterre,
France) according to the manufacturer’s protocol. Results were
expressed in nanograms per mL. The total number of HuC/HuD-
immunoreactive neurons was counted in the entire culture well
treated by LPS and TI and expressed as percentage of the number of
total neurons in control wells (see immunohistochemistry).
Cell viability was assessed using the Celltiter 96 Aqueous non-
radioactive cell proliferation 3-(4,5-dimethylthiazol-2-yl)-5-(3-car-
boxymethoxyphenyl)-2-(4-sulphophenyl)-2H-tetrazolium assay
(Promega, Charbonnieres-les-Bains, France, Cat#G3582). Primary
culture of rat ENS was cultured in 12-well plates and treated as
described above. After removal of the medium, CellTiter 96
Aqueous One Solution reagent was added to each well, according
to the manufacturer’s instructions. Neuronal viability was deter-
mined by measuring absorbance at 490 nm.
Filter trap assay
Ten micrograms of cell lysates was subjected to vacuum ﬁltration
through a 96-well dot blot apparatus (Bio-Rad, Marnes-la-Coquette,
France, Cat#1706545) with 0.45 lm pore size cellulose acetate
membranes (Sterlitech, Kent, OH, USA, Cat#CA0453001). Samples
of frozen temporal cortex from one post mortem human brain with
dementia with Lewy bodies were obtained from the Neuropathology
Department of Angers (Dr Franck Letournel) and were processed in
the same way to serve as a control. The resultant membranes were
processed as indicated in the western blot section using rabbit
monoclonal anti-human alpha-synuclein MJFR1 (1 : 1000; Abcam,
Cat# ab138501, RRID:AB_2537217) for dementia with Lewy
bodies samples or rabbit monoclonal anti-rat alpha-synuclein
D37A6 (1 : 500; Cell-Signaling, Cat#4179, RRID:AB_1904156)
antibodies for cell lysates.
Statistics
GraphPad Prism software version 7.05 (GraphPad Software Inc., La
Jolla, CA, USA) was used for statistical analysis. Because data were
not normally distributed according to the Kolmogorov–Smirnov
test, we used non-parametric tests. The differences between groups
were calculated by a Mann–Whitney U-test. The effects of
SB203580 on LPS- and TI-induced down-regulation of alpha-
synuclein in western blots were analyzed with a Kruskal–Wallis
non-parametric ANOVA test, followed by Dunn’s post hoc test. No
sample size calculation and no blinded analysis were performed. No
test for outliers was conducted on the data.
Results
Alpha-synuclein is expressed by neurons in primary culture
of rat ENS
After 17 days of culture, enteric neurons (Hu immunostaining,
Fig. 1a) were organized in ganglia connected to each other by
interganglionic ﬁber strands as demonstrated by b-tubulin III
immunostaining (Fig. 1b). Enteric glial cells, identiﬁed by
S100-b immunostaining, were also present in enteric ganglia
and along interganglionic ﬁber strands (Fig. 1a and c). This
neuronal network laid on a smooth muscle cells monolayer
(Fig. 1a). Immunolabelling with two different anti-alpha-
synuclein antibodies revealed that alpha-synucleinwas present
in the cytoplasm of the soma of enteric neurons (Fig. 1b and
Figure S1). A subset of enteric neurons expressed alpha-
synuclein in both the nucleus and the cytoplasm of the soma
(Fig. 1b and Figure S1). By contrast, alpha-synuclein was not
expressed by enteric glial cells (Fig. 1c).
LPS and TNF-a/IL1-b decrease the expression levels of
alpha-synuclein in primary culture of ENS
Primary culture of rat ENS expresses the LPS receptor TLR4
(Coquenlorge et al. 2014) (Figure S2a and b) as well as the
receptors for TNF-a and IL1-b (Gougeon et al. 2013). To
determine whether inﬂammation alters alpha-synuclein
expression, we treated primary culture of rat ENS with 0.1
lg/mL LPS and a combination of two pro-inﬂammatory
cytokines TNF-a and IL1-b (TNF-a/IL1-b, 10 nM each,
hereafter referred to as TI) for 72 h. Such concentrations of
LPS, TNF-a, and IL1-b were not neurotoxic in previous
reports that used cultured ENS (Gougeon et al. 2013;
Coquenlorge et al. 2014; Voss and Ekblad 2014). Cell lysates
were analyzed by western blot with two anti-alpha-synuclein
antibodies [(C20)-R and Syn-1] that recognize different
epitopes (Perrin et al. 2003; Preterre et al. 2015). Both TI
and LPS caused a signiﬁcant decrease in the amount of alpha-
synuclein in primary culture of ENS (Fig. 2a and b). We
veriﬁed that both treatments did not affect cell viability, as
determined by measurement of NSE release into the culture
medium, 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxy-
phenyl)-2-(4-sulphophenyl)-2H-tetrazolium assay, and count-
ing of Hu-immunoreactive cells (Fig. 2c). The decrease in
alpha-synuclein protein in response to LPS and TI was
accompanied by a signiﬁcant down-regulation at the mRNA
level (Fig 2d). Treatment with either LPS or TI did not induce
alpha-synuclein aggregation (Fig 2e) and did not change the
subcellular localization of alpha-synuclein (Fig. 1b and Fig-
ure S1). By contrast to TNF-a and IL1-b, other pro-
inﬂammatory cytokines including interleukins-6 and -10 and
interferon-c had no signiﬁcant effects on alpha-synuclein
expression (Fig. 2f).
The effects of LPS and TI on alpha-synuclein expression are
mediated through a p38 signaling pathway
Both JNK and p38 signaling pathways are strongly
activated by inﬂammatory mediators in numerous cell
types (Hotamisligil and Davis 2016). To determine the
respective role of these two signaling pathways on alpha-
synuclein expression, we used antibodies speciﬁc for the
dually phosphorylated active forms of p38 and JNK
together with speciﬁc inhibitors of these two kinases. TI
caused a rapid and transient activation of p38 in primary
culture of ENS (Fig 3a), while LPS induced a more
delayed and more sustained activation of the kinase
(Fig. 3b). To further investigate the role of p38 signaling
pathway in alpha-synuclein expression, we used two
different structurally unrelated p38 inhibitors SB 203580
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(Cuenda et al. 1995) and BIRB 796 (Pargellis et al. 2002).
We ﬁrst evaluated the efﬁcacy of these two compounds in
primary culture of ENS by showing that they efﬁciently
decreased the phosphorylation of the p38 downstream
target heat-shock protein 27 (Figure S4). Treatment with
SB 203580 (10 lM) or BIRB 796 (1 lM) for 72 h induced
a signiﬁcant increase in the expression levels of alpha-
synuclein (Fig. 3c and d). Treatment with SB 203580 fully
reversed the TI- and LPS-induced down-regulation of
alpha-synuclein (Fig. 3e). TI and LPS had only a marginal
effect on JNK phosphorylation (Figure S3a and b) and no
change in alpha-synuclein expression levels was observed
following JNK inhibition by 6o (Figure S3c).
LPS and TI have no effects on alpha-synuclein expression in
primary CNS neurons and HEL cells
In order to determine whether the effects of LPS and TI on
alpha-synuclein expression are speciﬁc to enteric neurons,
we used primary culture of rat CNS neurons and human
erythroleukemia (HEL) cell line, which both constitutively
express alpha-synuclein (Dettmer et al. 2013; Corbille et al.
2016). No changes in the expression levels of alpha-
Fig. 1 Distribution and localization of alpha-
synuclein in primary culture of rat enteric
nervous system (ENS) under basal
condition and after treatment with
lipopolysaccharide (LPS) and tumor
necrosis factor-a and interleukin 1-b (TNF-
a/IL1-b). (a) Primary culture of rat ENS at
14 days in vitro was immunolabeled with
anti-Hu, anti-S100-b, and anti-a-smooth
muscle actin antibodies. Scale bar is
50 lm. (b) After 14 days in culture,
primary culture of rat ENS was treated with
0.1 lg/mL LPS, 10 nM TNF-a/IL1-b (ΤΙ), or
vehicle (C, control) for 72 h, then
immunostained with Syn-1 and anti-b-
tubulin III antibodies. Scale bar is 25 lm.
(c) Primary culture of rat ENS at 14 days
in vitro was immunolabeled with Syn-1 and
anti-S100-b antibodies. Scale bar is 50 lm.
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synuclein were observed after a 72 h-treatment with either
LPS or TI in these two cell types (Fig. 4a and b). In addition,
and by contrast to primary culture of rat ENS, treatment of
primary CNS neurons and HEL cells with SB 203580 had no
effect on alpha-synuclein expression (Fig. 4c and d and
Figure S4).
Fig. 2 Effects of lipopolysaccharide (LPS) and pro-inﬂammatory
cytokines on the expression of alpha-synuclein in primary culture of
rat enteric nervous system (ENS). (a and b) After 14 days in culture,
primary culture of rat ENS was treated with vehicle (phosphate buffer
saline, control), 0.1 lg/mL LPS, or 10 nM TI for 72 h. Cell lysates were
subjected to immunoblot analysis using two different antibodies
speciﬁc for alpha-synuclein (C20-R and Syn-1). Membranes were
probed with anti-PGP9.5 antibodies to ensure equal loading of
neuronal proteins. Values represent mean  SEM (n = 8 and 14 per
condition for LPS and TI, respectively; treated vs. control *p < 0.05;
**p < 0.01). (c) Cell survival and viability were evaluated by measuring
the release of neuron-speciﬁc enolase in the culture medium (left, in
ng/mL), performing an 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxy-
methoxyphenyl)-2-(4-sulphophenyl)-2H-tetrazolium assay (middle,
expressed as percentage of controls) and by Hu neuronal counting
(right, expressed as percentage of controls). Three representative Hu
staining are shown, scale bar 25 lm). Values represent mean  SEM
(n = 4, 12, and 6, respectively). (d) Quantitative PCR analysis of alpha-
synuclein mRNA in primary culture of rat ENS treated after 14 days
in vitro with vehicle (control), LPS, or TI for 24, 48, or 72 h. Values
represent mean  SEM (n = 10–20 samples per condition; treated vs.
control *p < 0.05; **p < 0.01). (e) Lysates from primary culture of ENS
treated with LPS, TI, and vehicle (control) for 72 h were subjected to
ﬁlter trap assay analysis with cellulose acetate membrane using anti-
rat alpha-synuclein D37A6 antibody. Samples from dementia with
Lewy bodies brain served as control and were analyzed with anti-
human alpha-synuclein MJFR1 antibody. Data shown are represen-
tative of four independent experiments. (f) After 14 days in culture,
primary culture of rat ENS was treated with vehicle (control), 10 nM
interleukin-6 (IL-6), IL-10, and interferon-c (IFN-c) for 72 h. Cell lysates
were subjected to immunoblot analysis and quantiﬁcation was
performed as described in (a) (n = 4). IB is for immunoblot.
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Acute but not chronic DSS-induced colitis is associated with
a decreased expression of alpha-synuclein
To determine whether inﬂammation impacts alpha-synuclein
expression in vivo, we used two models (acute and chronic)
of DSS-induced colitis in mice. The colonic pro-
inﬂammatory cytokines expression proﬁle for each model
is shown in Figure S5. In the acute/severe model of colitis,
which was induced by a 4-day 4% DSS regimen, we
observed a signiﬁcant decrease in the expression levels of
alpha-synuclein in the distal colon at day 1 and day 3
Fig. 3 Roles of the p38 signaling pathway on lipopolysaccharide
(LPS)- and tumor necrosis factor-a/interleukin 1-b-induced down-
regulation of alpha-synuclein. (a and b) After 14 days in culture,
primary culture of rat enteric nervous system (ENS) was treated with
vehicle (control), with TI for 5, 15, 30, and 60 min or with LPS for 15,
30, 60, 180, and 480 min. Cell lysates were subjected to immunoblot
analysis using antibodies speciﬁc for the dually phosphorylated
(active) forms of p38 (℗-p38). After stripping the membranes were
reprobed with total p38 antibody. The values of active phospho-p38
were normalized to the amount of total p38. Values represent
mean  SEM (n = 4–8 samples per condition; treated vs. control
*p < 0.05; **p < 0.01). (c) Primary culture of rat ENS was treated with
vehicle (control) or 10 lM of the p38 inhibitor SB203580 for 72 h and
cell lysates were subjected to immunoblot analysis with anti-alpha-
synuclein antibody (C-20)-R. Values represent mean  SEM (n = 15;
treated vs. control **p < 0.01). (d) Primary culture of rat ENS was
treated with vehicle (control) or 1 lM of the p38 inhibitor BIRB 796 for
72 h and cell lysates were subjected to immunoblot analysis with anti-
alpha-synuclein antibody Syn-1. Values represent mean  SEM
(n = 8; treated vs. control *p < 0.05). (e) Primary culture of ENS was
treated with either LPS or TI for 72 h in the absence () or presence
(+) of 10 lM SB203580 and cell lysates were subjected to immunoblot
analysis with anti-alpha-synuclein antibody Syn-1. Values represent
mean  SEM (n = 8–14; treated vs. control *p < 0.05; treated in the
presence of SB203580 vs. in its absence: #p < 0.05). IB is for
immunoblot.
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(Fig. 5a) when compared to control animals (a trend
approaching but not reaching signiﬁcance was observed at
days 2 and 4, data not shown). By contrast, when a more
chronic model of colitis (three cycles of 2% DSS for 2 days
followed by 5 days of water) was used, no changes in the
expression levels of alpha-synuclein were observed between
treated and control animals.
Discussion
Despite the growing evidence linking inﬂammation to PD
development, very few studies have directly examined the
effects of inﬂammatory mediators on alpha-synuclein expres-
sion in cell lines (Tanji et al. 2001) and our study is the ﬁrst
performed in enteric neurons. We show that both LPS and TI
down-regulate alpha-synuclein expression at both mRNA
and protein levels in primary culture of rat ENS, but not in
primary culture of rat cortical neurons and in HEL cells. It is
unlikely that the lack of effects in CNS neurons and erythroid
cells is due to an absence of receptors, as current and
previous observations have shown that both cell types
express functional TLR4, TNF, and interleukins receptors
(Inoue et al. 2006; Wang et al. 2013). One possible
explanation may be that the enteric glia and smooth muscle
cells, which are present in cultured ENS may contribute to
the LPS- and TI-induced phenotypes in non-cell autonomous
ways. Another explanation might come from intrinsic
differences between the neuron subtypes. In an elegant
article, Rideout et al. compared the regulation of alpha-
synuclein levels between different subtypes of rat primary
CNS neurons and showed that basic ﬁbroblast growth factor
promoted alpha-synuclein expression within dopaminergic,
but not GABAergic or cortical neurons (Rideout et al. 2003).
An increase in intracellular cAMP, either induced by non-
hydrolyzable analogs or by b2 adrenoreceptor activation,
down-regulated alpha-synuclein in PC12 and human neu-
roblastoma cell line (Stefanis et al. 2001; Mittal et al. 2017),
while an opposite effect was observed in primary ENS
culture (Paillusson et al. 2010). Such a speciﬁc regulation of
alpha-synuclein might be relevant in the context of PD as the
disruption of transcriptional regulation in different neuronal
populations could underlie the clinical and neuropathological
heterogeneity observed in this neurodegenerative disorder
(Leclair-Visonneau et al. 2018).
So far, most existing studies on alpha-synuclein expression
in neurons have identiﬁed the extracellular signal–regulated
kinases (ERK) pathway as being a key player. The induction
of alpha-synuclein by growth factors in PC12 cells is ERK
dependent (Clough and Stefanis 2007) as is the regulation of
alpha-synuclein expression by neuronal activity in cultured
ENS (Paillusson et al. 2010). We show in this study that the
p38 signaling pathway is also critically involved in the
Fig. 4 Effects of lipopolysaccharide (LPS),
tumor necrosis factor-a/interleukin 1-b, and
SB203580 on the expression of alpha-
synuclein in primary culture of rat CNS
neurons and human erythroid leukemia
(HEL) cells. (a) Primary cultures of rat
cortical neurons were treated with vehicle
(control), 0.1 lg/mLLPS, or 10 nM TI for
72 h and cell lysates were subjected to
immunoblot analysis with anti-alpha-
synuclein antibody Syn-1. Values
represent mean  SEM (n = 15). (b) HEL
cells were treated with vehicle (control), 0.1
lg/mL LPS, or 10 nM TI for 72 h and cell
lysates were subjected to immunoblot
analysis with anti-alpha-synuclein antibody
(C-20)-R. (c and d) Primary cultures of rat
cortical neurons and HEL cells were treated
with vehicle (control) or 10 lM SB203580
for 72 h and cell lysates were subjected to
immunoblot analysis with anti-alpha-
synuclein antibody Syn-1. Values
represent mean  SEM (n = 10 and 6,
respectively). IB is for immunoblot.
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regulation of alpha-synuclein expression in enteric neurons.
By contrast to primary cortical neurons, two different p38
inhibitors dramatically increased the expression levels of
alpha-synuclein in primary culture of ENS, thereby suggest-
ing that the amount of alpha-synuclein is tonically down-
regulated in enteric neurons via a p38 signaling pathway. In
addition, we showed that the effects of either TI or LPS on
enteric alpha-synuclein expression were completely reverted
in the presence of the p38 inhibitor SB203580. Our current
results, together with our previous ﬁndings (Paillusson et al.
2010), indicate that the ERK inhibitor U0126 and the p38
inhibitor SB203580 have an opposite effect on alpha-
synuclein expression in primary culture of ENS, inducing a
down- and up-regulation of alpha-synuclein, respectively.
They therefore strongly support the existence of a cellular
signaling network in enteric neurons in which alpha-
synuclein expression level is regulated by a cross-talk
between ERK and p38.
In order to extend our results obtained in vitro, we studied
the expression levels of alpha-synuclein in the colon of mice
with DSS-induced acute colitis. Acute, chronic, and relapsing
models of intestinal inﬂammation can be achieved by
modifying the concentration of DSS as well as the frequency
of administration and clinical signs of disease appear as soon
as 1 day post-treatment, with an increased expression of the
main pro-inﬂammatory cytokines (Yan et al., 2009). In
agreement with our results obtained in vitro, we observed a
decreased expression of alpha-synuclein in the acute model
of DSS-induced acute colitis. By contrast, when a more
chronic administration regimen was used, we did not observe
any change in the alpha-synuclein levels. Such a discrepancy
might be explained by the lower levels of colonic pro-
inﬂammatory cytokines that were found in this model when
compared to the acute regimen (Garrido-Gil et al. 2018).
These observations further reinforce the possible role of pro-
inﬂammatory cytokines and especially TNF-a and IL1-b in
Fig. 5 Alpha-synuclein expression in the
colon of mice with DSS-induced colitis. (a)
Acute colitis was induced in mice by 4%
DSS in the drinking water for 4 days.
Lysates from colonic samples from day 1
to day 4 were subjected to immunoblot
analysis using Syn-1, PGP 9.5 and beta-
actin antibodies. Values represent
mean  SEM (n = 5 per condition and per
day; treated vs. control *p < 0.05). (b)
Chronic colitis was obtained by three
cycles of 2% DSS in drinking water for
2 days followed by 5 days of water. Lysates
from colonic samples at day 18 were
subjected to immunoblot analysis using
Syn-1, PGP 9.5 and beta-actin antibodies.
Values represent mean  SEM (n = 10 per
condition).
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the regulation of enteric alpha-synuclein level. In further
experiments, it will be interesting to study if alpha-synuclein
is up-regulated in a model of slowly progressive colitis that
can be induced by administering 4–5 repeated cycles of DSS.
At ﬁrst glance, our results seem at odds with two recently
published studies that reported an increase in alpha-
synuclein levels in humans with either acute or chronic GI
inﬂammation (Stolzenberg et al. 2017; Prigent et al. 2018).
In children who received intestinal transplant, norovirus
virus infection induced a marked and persistent elevation in
alpha-synuclein in the upper-GI tract (Stolzenberg et al.
2017). We recently showed that the expression levels of
alpha-synuclein is increased in patients with chronic
inﬂammatory disorders of the GI tract, such as Crohn’s
disease (Prigent et al. 2018). A possible explanation for the
discrepancy between these results and our current ﬁndings
may be related to the mechanisms involved in the regulation
of alpha-synuclein levels in each model. As suggested by
Stolzenberg et al. (2017), the greater amount of alpha-
synuclein observed in the mucosa of norovirus-infected
children likely results from a mobilization of the protein
within the ENS, which is part of a normal immune defense
mechanism. Regarding Crohn’s disease, our unpublished
results suggest that the up-regulation of alpha-synuclein is
not transcriptionally mediated but is instead due to a
decrease in protein degradation.
On the basis of increasing evidence showing that PD
patients exhibit inﬂammation in the gut (Devos et al. 2013),
several authors have proposed a model for PD pathogenesis.
In such a model, an hitherto unknown pathogen triggers
intestinal inﬂammation, which in turn would induce intestinal
hyperpermeability, to increase the expression and aggrega-
tion of alpha-synuclein in neurons of the submucosal plexus
whose terminal axons are only micrometers away from the
gut lumen (Lema Tome et al. 2013; Houser and Tansey
2017). The pathological process would further spread to the
CNS via the vagal preganglionic innervation of the gut, as
this has been already demonstrated for prion (Kujala et al.
2011) and neural tracers (Walter et al. 2009). In this context,
our results suggest that if alpha-synuclein is up-regulated by
GI inﬂammation in PD, it is not through a direct increase in
protein synthesis. Therefore, at this time, it remains unclear
whether the observed changes in inﬂammatory markers in
PD patients are an initial occurrence that contributes to the
development of the disease, or if they emerge in response to
PD-related pathology in the enteric neurons or enteric glial
cells (Beach et al. 2010; Clairembault et al. 2014).
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Authors who wish to publicly post third-party material in their data, materials, or preregistration 
plan must have the proper authority or permission agreement in order to do so.  
 
There are circumstances in which it is not possible or advisable to share any or all data, 
materials, or a research plan publicly. For example, there are cases in which sharing 
participants’ data could violate confidentiality. If you would like your article to include an 
explanation of such circumstances and/or provide links to any data or materials you have made 
available—even if not under conditions eligible to earn a badge—you may write an alternative 
note that will be published in a note in the article. Please check this box if you would like your 
article to include an alternative note and provide the text of the note below:  
 
[] Alternative note:  
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[] Open Data Badge 
  
1.  Provide the URL, doi, or other permanent path for accessing the data in a public, open-
access repository:  
 
 
[] Confirm that there is sufficient information for an independent researcher to reproduce 
all of the reported results, including codebook if relevant. 
 
[] Confirm that you have registered the uploaded files so that they are time stamped 
and cannot be age. 
 
[X] Open Materials Badge 
 
1. Provide the URL, doi, or other permanent path for accessing the materials in a 
public, open-access repository: all relevant information is provided in the manuscript and 
custom-made materials will be provided upon reasonable request. 
 
 
[X] Confirm that there is sufficient information for an independent researcher to 
reproduce all of the reported methodology. 
 
[] Confirm that you have registered the uploaded files so that they are time stamped 
and cannot be age. 
 
 
 [] Preregistered Badge 
 
1. Provide the URL, doi, or other permanent path to the registration in a public, 
open-access repository*: 
  
 
2. Was the analysis plan registered prior to examination of the data or observing the outcomes? 
If no, explain.** 
 
 
3. Were there additional registrations for the study other than the one reported? If yes, provide 
links and explain.* 
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*No badge will be awarded if (1) is not provided, or if (3) is answered “yes” without strong 
justification 
 
**If the answer to (2) is “no,” the notation DE (Data Exist) will be added to the badge, indicating 
that registration postdates realization of the outcomes but predates analysis.  
 
By signing below, authors affirm that the above information is accurate and complete, that any 
third-party material has been reproduced or otherwise made available only with the permission 
of the original author or copyright holder, and that publicly posted data do not contain 
information that would allow individuals to be identified without consent.  
 
 
  
Date:   December 21, 2018 
 
 
Name:  Pascal Derkinderen 
 
 
Signature:   
 
 
 
 
 
 
